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Abstract
Evidence is growing for a role of Waddlia chondrophila as an agent of adverse pregnancy outcomes in both humans and
ruminants. This emerging pathogen, member of the order Chlamydiales, is also implicated in bronchiolitis and lower
respiratory tract infections. Until now, the serological diagnosis of W. chondrophila infection has mainly relied on manually
intensive tests including micro-immunofluorescence and Western blotting. Thus, there is an urgent need to establish
reliable high throughput serological assays. Using a combined genomic and proteomic approach, we detected 57
immunogenic proteins of W. chondrophila, of which 17 were analysed by mass spectrometry. Two novel hypothetical
proteins, Wim3 and Wim4, were expressed as recombinant proteins in Escherichia coli, purified and used as antigens in an
ELISA test. Both proteins were recognized by sera of rabbits immunized with W. chondrophila as well as by human W.
chondrophila positive sera but not by rabbit pre-immune sera nor human W. chondrophila negative sera. These results
demonstrated that the approach chosen is suitable to identify immunogenic proteins that can be used to develop a
serological test. This latter will be a valuable tool to further clarify the pathogenic potential of W. chondrophila.
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Introduction
Waddlia chondrophila is an emerging pathogen belonging to the
Chlamydiales order, which currently includes six different family-
level lineages: the Chlamydiaceae, the Parachlamydiaceae, the Wad-
dliaceae, the Simkaniaceae, the Criblamydiaceae and the Rhabdochlamy-
diaceae [1,2]. All members of the Chlamydiales order exhibit a strict
intracellular life cycle, with most undergoing a biphasic develop-
mental cycle, beginning with an infectious, but metabolically
inactive, elementary body (EB) entering its host cell by endocytosis
and converting to a metabolically active reticulate body (RB)
replicating by binary fission. At the end of the replication cycle,
RBs redifferentiate into EBs, that are released by lysis of the host
cell to initiate a new infection cycle [3].
The Chlamydiaceae family comprises well-known human and
animal pathogens, of which several are implicated in adverse
pregnancy outcomes and in respiratory tract infections in humans
and in animals [4,5,6]. In recent years, attention has also turned to
members of the Parachlamydiaceae, Simkaniaceae and Waddliaceae
families, considered to be possible emerging human and animal
pathogens. Simkania negevensis and Parachlamydia acanthamoebae are
likely implicated in lower respiratory tract infections in humans
[7,8,9]. Recent reports also indicate an association of P.
acanthamoebae with abortion in ruminants [10,11] and with human
fetal loss [4,12].
W. chondrophila is considered as an abortigenic agent in
ruminants. It was isolated from aborted bovine fetuses on two
separate occasions, once in USA and once in Germany [13,14].
Furthermore, a serological study has demonstrated a clear
association between anti-Waddlia antibodies and bovine abortion
[15] and experimental infection of 2 fetuses with W. chondrophila led
to the death of one within 2 weeks [15]. A pathogenic role of W.
chondrophila in humans is supported by a serological study
conducted on women having experienced sporadic or recurrent
miscarriage, which demonstrated a strong association between W.
chondrophila seropositivity and adverse pregnancy outcomes [16]. In
addition, we recently implemented a real time quantitative PCR
for the detection of this pathogen [17] and could report the
presence of W. chondrophila DNA in placenta sample of a woman
suffering from miscarriage [18]. Waddlia chondrophila was also
detected in respiratory tract samples of patients with pneumonia
and children with bronchiolitis [17,19].
Given its obligate intracellular life cycle, W. chondrophila cannot
be grown routinely on culture plates used to reveal pathogens and
thus would remain undetected by conventional microbiological
methods. In humans, the aetiology of miscarriage remains
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unknown in 50% of cases [16] and there is a clear need for
improved methods to detect potential agents such as W.
chondrophila. Until now, methods used to detect W. chondrophila
infection have relied mainly on molecular techniques [17] or
indirectly via seropositivity in micro-immunofluorescence or
Western blots [16]. The latter are particularly time consuming
and poorly applicable for screening large numbers of samples.
Therefore, to further determine the pathogenic role of W.
chondrophila in humans and in animals, there is an urgent need to
identify immunogenic proteins and to establish a reliable ELISA
test.
We recently reported the use of a combined genomic and
immuno-proteomic approach, to identify immunogenic proteins of
Parachlamydia acanthamoebae [20]. The same approach has also been
used to identify immunoreactive proteins of Bartonella quintana and
Bartonella henselae [21,22,23]. In this study, we combined an
immunoproteomic method, i.e. a technique involving 2 dimen-
sional gel electrophoresis followed by immunoblotting, with the
complete genomic data of W. chondrophila that became recently
available [24], to identify W. chondrophila immunogenic proteins
and to establish the basis for a serological diagnostic test.
Results
2D map of W. chondrophila immunoreactive proteins
To identify immunoreactive proteins that could be used in a
diagnostic test, elementary bodies of W. chondrophila were lysed and
their proteins extracted and separated by 2 dimensional,
polyacrylamide gel electrophoresis (2D gels). Bacterial proteins
were subsequently either transferred onto nitrocellulose mem-
branes or Coomassie-blue stained. To verify that the purification
procedure retrieved only waddlial proteins, we also performed a
2D gel with proteins extracted from a mock control. Coomassie
blue staining of this negative control revealed a total absence of
proteins (data not shown). To detect immunoreactive proteins,
blots were incubated with the serum of a rabbit immunized with
W. chondrophila or with the sera of 13 patients previously tested
positive for W. chondrophila by immunofluorescence [16,25]. With
the help of the Adobe Photoshop Software, the immunoreactive
spots were matched with their corresponding proteins on the
Coomassie blue-stained gel, which allowed the detection of 57
immunoreactive proteins (numbered 1 to 57 on Figure 1). The
level of recognition of these 57 individual proteins by the 13
human W. chondrophila positive sera tested varied considerably, one
being recognized by 92.31% of the sera (12/13) and others being
detected by only 1 of the 13 tested sera (7.69%).
To be manually picked from the gel and accurately analyzed by
mass spectrometry, a protein must be clearly stained by Coomassie
blue and form a well defined spot. We selected 16 protein spots
meeting these criteria as well as being recognized by at least 5
human W. chondrophila positive sera (of the 13 tested) and submitted
them to mass spectrometry analysis. Spot number 24 was
recognized by 4 sera, of which two very strongly, and was
included in the analysis (Table 1).
Identification of immunogenic proteins
MALDI TOF MS analysis of 17 individual spots corresponding
to immunoreactive proteins resulted in the identification of 13
different proteins, mainly already known chlamydial antigens and
proteins described as immunogenic in other bacterial species
[22,26] (Table 2). More interestingly, this immunoproteomic
method allowed the detection of two hypothetical proteins, spot
#3 (Wim3) and spots#4 and#7 (Wim4). Wim3 has no homology
with any known protein and is therefore a very promising
Figure 1. Coomassie blue-stained 2D map of the whole-protein extract of W. chondrophila. Proteins were transferred to nitrocellulose and
probed with 13 W. chondrophila positive human sera and with the serum of a rabbit immunized with W. chondrophila. Immunoreactive proteins are
numbered (1–57).
doi:10.1371/journal.pone.0028605.g001
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candidate for the development of a W. chondrophila specific ELISA
test. Wim4 displays no sequence homology with proteins of C.
trachomatis and of other members of the Chlamydiaceae family, but
partial homologs are found in the genomes of two members of the
Parachlamydiaceae family, P. amoebophila (pc1399, 34% identity) and
P. acanthamoebae (pah_c029o043, 41% identity) as well as in the
draft genomes of two members of the Criblamydiaceae family, Estrella
lausannensis (35% identity) and Criblamydia sequanensis (36% identity)
(C. Bertelli et al., unpublished results). The sequence homologies
are mainly restricted to the C-terminal region (last 100 amino acid
residues) of these related proteins. Moreover, the P. acanthamoebae
homolog of Wim4 has been previously identified as an
immunogenic protein [20]. Interestingly, the W. chondrophila gene
wcw_1618, encoding hypothetical protein #4 (Wim4), is located
in one of the four type III secretion system (T3SS) genetic clusters
present on the bacterial chromosome [24].
Western blot and ELISA with rabbit sera
Most of the 13 identified immunogenic proteins described above
have highly conserved homologs in the genomes of other
Chlamydiales bacteria (Table 2) and are thus likely to generate
cross-reactions if used in an ELISA test. For this reason, only the
two hypothetical proteins Wim3 and Wim4 were further
considered for the development of a W. chondrophila-specific
serological diagnostic tool. In silico analysis of their amino acid
sequences revealed the absence of signal peptides and transmem-
brane domains [27,28,29]. Both proteins were expressed in E. coli
and purified via a C-terminal His tag. The purified recombinant
proteins were detected by Western blot with a rabbit anti-Waddlia
serum but not with the corresponding pre-immune serum (data
not shown).
Both Wim3 and Wim4 were detected by sera of two rabbits
immunized with W. chondrophila in a direct ELISA assay. Serum of
rabbit #2 was reactive against the two proteins down to a dilution
of 1/256 while serum of rabbit #1 remained reactive at a dilution
of 1/4096. Only background reactions were observed with the
corresponding pre-immune sera (data not shown). This demon-
strated that Wim3 and Wim4 could be detected by the sera from
animals immunized with the whole bacterium, supporting their
potential use in a serological diagnostic test.
ELISA with human sera
To evaluate the sensitivity and specificity of Wim3 and Wim4
proteins in a W. chondrophila ELISA, we utilized 24 human sera
from a previous study [16] and we first determined their positivity
or negativity towards W. chondrophila using a micro-immunofluo-
rescence assay (MIF) as gold standard. The sera reactivity was then
assessed by direct ELISA using Wim3 and Wim4 as antigens. In
order to maximize the signal:noise ratio of these assays, we
performed optimization experiments in which various primary and
secondary antibody dilutions as well as different saturation and
washing conditions were compared. The optimal assay conditions
were determined using ROC analyses (Figure 2). In these
optimized conditions, the results obtained with 20 W. chondrophila
positive and 4 W. chondrophila negative human sera indicated that
both Wim3 and Wim4 assays are able to distinguish the two
groups of sera (Figure 3). Considering a threshold value of 0.63,
the sensitivity was 100% for the Wim3 assay and, with a threshold
value of 0.3, 90% for the Wim4 assay. In addition, sera negative
for W. chondrophila and for other members of the Chlamydiales order
were not detected neither in the Wim3 nor in the Wim4 assay
(specificity of 100% for both assays, see Figure 3).
Table 1. Reactivity of W. chondrophila positive sera towards 17 selected proteins.
Spot Human W. chondrophila positive sera
# A B C D E F G H I J K L M Frequency (%)
Rabbit
serum
1 ++ 2 ++ ++ ++ ++ ++ ++ 2 ++ 2 ++ ++ 76.92 2
2 ++ ++ ++ ++ ++ ++ ++ ++ 2 ++ ++ ++ ++ 92.31 ++
3 2 2 ++ ++ ++ 2 2 ++ 2 ++ 2 2 2 38.46 +
4 ++ ++ ++ ++ ++ ++ ++ ++ 2 ++ 2 ++ 2 76.92 +
5 ++ ++ ++ 2 ++ ++ ++ ++ 2 ++ ++ ++ ++ 84.62 +
6 ++ ++ ++ 2 ++ ++ 2 ++ 2 2 2 2 2 46.15 2
7 ++ ++ ++ 2 ++ 2 ++ ++ + + 2 + 2 69.23 2
11 ++ ++ ++ ++ ++ ++ ++ ++ ++ 2 ++ ++ 2 84.62 ++
13 2 + + + + + + + 2 + + + + 84.62 2
16 2 + 2 + + + + + + 2 2 + + 69.23 2
17 2 ++ 2 ++ ++ 2 ++ ++ 2 2 2 2 ++ 46.15 2
20 2 2 2 2 + + + + 2 2 2 2 + 38.46 2
21 2 + + + 2 + + 2 2 2 2 + 2 46.15 2
22 + + + + + + + 2 2 2 2 2 + 61.54 2
23 + + 2 ++ ++ + + 2 2 2 2 2 + 53.85 2
24 + 2 + ++ ++ 2 2 2 2 2 2 2 2 30.77 2
56 2 ++ ++ 2 ++ ++ ++ 2 2 2 2 2 2 38.46 2
The reactivity of 17 proteins of W. chondrophila selected for mass spectrometry analysis towards 13 human and 1 rabbit sera was investigated by western blot. The
signal intensities are presented semi-quantitatively: (2) negative, (+) positive, (++) strongly positive.
doi:10.1371/journal.pone.0028605.t001
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Table 2. Identification of 13 different immunogenic proteins of W. chondrophila and amino acid sequence identity with 2 related
organisms.
Spot number ORF Accession number2 Protein identification Amino acid sequences identity (%) with
(protein name)1 P. acanthamoebae C. trachomatis 434/Bu
1 (Wim1) wcw_0306 GENE ID: 9277285 fusA Elongation factor G 78 74
2 (Wim2) wcw_1638 GENE ID: 9278617 dnaK Chaperone protein DnaK 77 71
3 (Wim3) wcw_1327 GENE ID: 9278306 wcw_1327 Hypothetical protein No homolog No homolog
4 (Wim4) wcw_1618 GENE ID: 9278597 wcw_1618 Hypothetical protein 41 No homolog
5 (Wim5) wcw_0584 GENE ID: 9277563 tuf Elongation factor Tu 79 74
6 (Wim6) wcw_1934 GENE ID: 9278912 tsf Elongation factor Ts 65 41
7 (Wim4) wcw_1618 GENE ID: 9278597 wcw_1618 Hypothetical protein 41 No homolog
11 (Wim11) wcw_0859 GENE ID: 9277838 nusA Transcription elongation protein
NusA
75 61
13 (Wim2) wcw_1638 GENE ID: 9278617 dnaK Chaperone protein DnaK 77 71
16 (Wim16) wcw_1343 GENE ID: 9278322 groEL1 Chaperonin GroEL 81 75
20 (Wim20) wcw_0589 GENE ID: 9277568 rplA 50S ribosomal protein L1 70 58
21 (Wim21) wcw_0972 GENE ID: 9277951 pepA Leucyl aminopeptidase No homolog 46
22 (Wim22) wcw_1647 GENE ID: 9278626 rho Transcription termination factor
rho
85 79
23 (Wim23) wcw_0999 GENE ID: 9277978 lpdA2 2-oxoglutarate dehydrogenase E3
component
62 38
24 (Wim22) wcw_1647 GENE ID: 9278626 rho Transcription termination factor
rho
85 79
1Wim: Waddlia immunogenic protein,
2Genome accession number: GenBank CP001928.
Identification and amino acid sequence identities of each immunogenic protein identified by mass spectrometry are provided according to BLASTP results against a
non-redundant database.
doi:10.1371/journal.pone.0028605.t002
Figure 2. Optimization of ELISA conditions. A. ROC curves obtained using Wim 3 protein as antigen. Combination of buffers used for saturation
and dilution of antibodies as well as for washing steps were tested with sera positive and negative for W. chondrophila. See Material and Methods for
further description of the assay conditions. B. ROC curves obtained with the Wim3 assay using condition 2 and various dilution of primary and
secondary antibodies.
doi:10.1371/journal.pone.0028605.g002
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Discussion
W. chondrophila is now considered as an abortigenic agent in
ruminants [13,14,15] and as a possible cause of adverse pregnancy
outcome in humans [16,18]. Moreover, bacterial DNA has been
detected in respiratory tract samples from patients with pneumo-
nia and from children with bronchiolitis [17,19]. Recent
publications from our group documented the intracellular growth
of W. chondrophila in human macrophages, endometrial cells and
pneumocytes [30,31,32], which further underlines the pathogenic
potential of this organism for humans. At present, serological
investigation to diagnose W. chondrophila infection relies on a
tedious and time-consuming micro-immunofluorescence (MIF) test
[16,25]. Given its pathogenic potential, it is crucial to develop a
reliable, sensitive and specific ELISA test for assessing the
prevalence of this organism in the human population in large
sero-epidemiological studies.
In order to identify immunogenic proteins of W. chondrophila that
would be family-specific, we established a combined immunopro-
teomic and comparative genomics approach utilizing newly
available genomic data [24]. This led to the identification of
Waddlia proteins, homologs of known chlamydial immunogenic
proteins such as chaperonin GroEL (Hsp60), chaperone protein
DnaK (Hsp70), elongation factor Tu and leucyl aminopeptidase
[33,34,35] and of proteins, such as elongation factor G, elongation
factor Ts, transcription termination factor rho and 2-oxoglutarate
dehydrogenase E3 component which have been described as
immunogenic in other bacterial species [22,26]. This congruence
between our results and those reported by other scientists using
other approaches supports the relevance of our immunoproteomic
method to successfully identify immunogenic proteins. Further-
more, all proteins identified by mass spectrometry were of waddlial
origin, a result that reveals the purity of the bacterial preparation,
further confirmed by the complete negativity of the 2D gel
obtained with the mock control.
Four of the 13 identified proteins (chaperonin GroEL,
chaperone protein DnaK, elongation factor Tu and elongation
factor Ts) were also described as immunogenic in a similar work
conducted on P. acanthamoebae [20]. In addition, W. chondrophila
hypothetical protein #4 (Wim4), also identified in this work,
is homolog to a P. acanthamoebae hypothetical protein
(pah_c029o043), which was previously shown to be immunogenic
[20].
Commercially available ELISA tests for the diagnosis of
chlamydial infections are usually based on recombinant peptides
of the major outer membrane protein (MOMP) or of the 60 kDa
cysteine-rich outer membrane protein (OmcB), two major antigens
of the organisms belonging to the Chlamydiaceae family [33,36,37].
Although, no homolog to MOMP could be identified in the P.
acanthamoebae or in the P. amoebophila genomes, a putative cysteine-
rich MOMP-family is present in the W. chondrophila genome
[20,24,38]. However, no protein of this family was identified in the
Figure 3. Analysis of 24 human sera by ELISA. 96-well ELISA microplates were coated either with recombinant protein Wim3 or recombinant
protein Wim4. Human sera were previously characterized by MIF and are represented as follows: grey circles: W. chondrophila positive (n = 20); black
circles: W. chondrophila negative (n = 4). The bar indicates the mean value for each group. Threshold of positivity: 0.63 for Wim3 and 0.30 for Wim4.
Results are the mean of three independent experiments. Thresholds were determined by ROC curves analyses (GraphPadPrism).
doi:10.1371/journal.pone.0028605.g003
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present work, most probably because we had, on purpose, chosen
extraction and isolation conditions which should leave the putative
waddlial disulphide linked matrix as an insoluble complex. Since
our primary aim was to identify unique immunogenic proteins
which we could express as fusion-proteins in bacteria for use in a
high-throughput ELISA and since disulphide-rich fusion proteins
are notoriously difficult to prepare in this manner, we had decided
to leave this aspect for a later date. This strategy has the added
advantage of easing the preparation of clean 2D gels for proteomic
analysis and immunoblotting.
In addition, several other proteins, such as ribosomal proteins
S1 and L7/L12, chlamydial protease-like activity factor (CPAF),
translocated actin-recruiting protein (TARP) and polymorphic
membrane protein D (PmpD), which are well-described antigens
of Chlamydiaceae [34,35,39,40] were also not detected in our study
on W. chondrophila. Since the corresponding genes are indeed
present in the Waddlia genome, these proteins are likely among
those that were not chosen for analysis by mass spectrometry,
being either weakly immunogenic or poorly expressed in
elementary bodies. Alternatively, large proteins such as the
waddlial putative Pmp could be under represented due to the
2D gel limitations for large proteins.
Despite these limitations, our strategy proved to be successful,
with 2 novel proteins (Wim3 and Wim4) selected (from the 13
identified immunogenic proteins) as promising candidates for the
development of a Waddlia-specific ELISA since they display little or
no sequence homology with proteins of other members of the
Chlamydiales order. Indeed, one recurrent problem of previous
serological studies in the chlamydial field was the possible cross
reactivity of highly conserved proteins, such as Hsp60, with different
bacteria of the same phylogenic order. This limitation was
overcome in the present study by the use of a protein not encoded
in the genome of any Chlamydiales bacteria sequenced today
[20,41,42]. In Western blot as well as in ELISA, both recombinant
proteins Wim3 and Wim4 reacted with the sera of rabbits
immunized with W. chondrophila and not with the corresponding
pre-immune sera thus confirming the potential of these two proteins
for use in a diagnostic serological test. Wim3 and Wim4 were used
in ELISA to assess the reactivity of human sera previously tested by
a micro-immunofluorescence (MIF) technique (considered as the
gold standard for serological diagnosis) towards W. chondrophila. The
sensitivity of the ELISA was 100% for the assay with Wim3 and
90% for the assay with Wim4, using cut off values of 0.63 for the
Wim3 assay and of 0.3 for the Wim4 assay, respectively. When
considering W. chondrophila negative sera, the specificity of both
assays was 100% with the defined cut off values. Thus, the results
obtained with Wim3 and Wim4 ELISA were congruent with those
obtained byMIF in 100% and 92% of the cases respectively, despite
the fact that the antibody response measured is directed against one
specific protein in the ELISA and against the whole bacterium in
the MIF tests.
In conclusion, by combining genomic and proteomic approach-
es, this work allowed the identification of an immunogenic protein
set for W. chondrophila, of which a number are highly conserved
homologs of well-known chlamydial antigens. In addition, we also
reported the immunoreactivity of two novel proteins of unknown
function, one (Wim3) being specific to W. chondrophila. Preliminary
experiments indicated that a direct ELISA test using Wim3 as
antigen is able to discriminate between Waddlia positive and
Waddlia negative sera as efficiently as micro-immunofluorescence
and could be used as an alternative to screen large numbers of
samples. Further work is now needed to precisely establish the
specificity of this assay, in particular towards other members of the
Chlamydiales order.
Methods
Human sera
Human sera were described in previous studies [16,25]. The
clinical studies were approved by the local ethical committees. All
sera were tested with an in-house micro- immunmofluorescence
method (see below) for reactivity against W. chondrophila. In
addition, negative sera were also tested for reactivity against other
members of the Chlamydiales order (P. acanthamoebae, E. lausannensis,
C. sequanensis, S. negevensis, N. hartmannellae, C. trachomatis, C.
pneumoniae and C. psittaci) [16].
Sera from immunized rabbits
Rabbit anti-W. chondrophila sera were obtained by vaccination
with W. chondrophila strain ATCC VR-1470 grown in amoebae (see
below). Briefly, rabbits were inoculated at days 0, 14, 28 and 56
with 500 ml of PBS containing 56108 heat-inactivated W.
chondrophila. Animals were bled prior to immunization (pre-
immune sera) and at day 90.
Culture and purification of Waddlia chondrophila
W. chondrophila strain ATCC VR-1470 was grown at 32uC
within Acanthamoeba castellanii strain ATCC 30010 in 25 cm2 or
75 cm2 cell culture flasks (Corning, New York, USA) with 10 or
30 ml of peptone-yeast extract-glucose broth and purified using a
sucrose barrier and a gastrografin gradient, as previously described
[6,43]. The same purification procedure was also performed on
non-infected A. castellanii (mock control). The purified bacteria
were conserved in PBS and 20% glycerol at 280uC.
Crude extract sample preparation and 2D gel
electrophoresis
Bacterial cells resuspended in PBS were washed in 10 mM Tris,
5 mM Magnesium acetate, pH 8.0 and then lysed by 5 cycles of
short-pulse sonication in lysis buffer (30 mM Tris, 7 M urea, 2 M
thiourea, 4% CHAPS, pH 8.5). Proteins were recovered by
centrifugation at 6’000 g and their concentration determined
using a Bradford assay (Quick StartTM Bradford Protein Assay,
Biorad, Hercules, USA).
Two dimensional gel electrophoresis was performed as
described by Centeno et al. [44] using approximately 150 mg
(mini gels) or 600 mg (midi-gels) of total elementary bodies
proteins. Proteins were visualized by Coomassie Blue staining or
transferred to nitrocellulose for subsequent immunoblot analyses.
Immunoblot analysis
Nitrocellulose membranes corresponding to 2D gels were blocked
by 2 hours incubation with 5% non-fat dry-milk in Tris-buffered
saline with 0.05% Tween 20 (TBS), washed 3 times with TBS, 0.5%
milk and incubated overnight at 4uC with sera diluted in TBS, 0.5%
milk. Membranes were probed either with human sera (dilution 1/8)
or with sera of immunized rabbits (dilution 1/25). After 3 subsequent
washes with TBS, 0.5% milk, membranes were incubated with
horseradish peroxidase-conjugated goat anti-human IgG (Chemi-
con, Temecula, CA, 1:500) or horseradish peroxidase-conjugated
goat anti-rabbit IgG (Cell Signaling, Allschwill, Switzerland,
1:1000). Finally, membranes were washed 3 times with TBS and
immunoreactive spots were detected either with a chemilumines-
cence-based kit (LiteAblotTM, Euroclone SpA, Pero, Italy) or with 4-
chloro-1-naphtol (Sigma-Aldrich, St. Louis, MO, USA).
The same protocol was used for 1D western blots on Wim3 and
Wim4 using sera of rabbits immunized with W. chondrophila or
preimmune sera at dilution 1/100.
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Mass spectrometry
For identification of proteins, Coomassie Blue stained spots
were excised from 2D gels and transferred to special 96-well plates
(Perkin Elmer Life Sciences). In-gel proteolytic cleavage with
sequencing-grade trypsin (Promega, Madison, WI, USA) was
performed in the automated workstation Investigator ProGest
(Perkin Elmer Life Sciences) according to the protocol of
Shevchenko et al. [45]. Digests were evaporated to dryness and
resuspended in 3 ml alpha-cyano-hydroxycinnamic acid matrix
(5 mg/ml in 60% (v:v) acetonitrile:water), of which 0.7 ml were
deposed in duplicate on a target plate.
MALDI-MS-MS analysis was performed on a 4700 Proteomics
Analyser (Applied Biosystems, Framingham, MA, USA). After
MALDI-TOF MS analysis, internal calibration on trypsin autolysis
peaks and subtraction of matrix peaks, the 10 most intense ion
signals were selected for MS/MS analysis. Non-interpreted peptide
tandem mass spectra were used for direct interrogation of W.
chondrophila open reading frames using Mascot 2.0 (http://www.
matrixscience.com). The mass tolerance for database searches was
50 ppm. With the parameters used, the threshold for statistical
significance (p,0.05) corresponded to a MASCOT score of 17, but
only scores greater than 30 were considered. Proteins scoring above
80 were automatically considered as valid, while all protein scoring
between 30 and 80 were manually validated. Validation included
examination of the peptide mass error of individual peptide
matches. When proteins could not be identified by MALDI-TOF
MS analysis, spots were reanalyzed by LC-MS followed by the same
identification procedure as described above.
Cloning, expression and purification of immunogenic
proteins
The ORFs corresponding to the immunogenic proteins #3
(Wim3);(ORF wcw_1327) and #4 (Wim4);(ORF wcw_1618) were
amplified by PCR and cloned into the pET28 vector (Novagen
EMD Chemicals Inc, San Diego, USA). This vector system allows
to express the protein of interest fused with a C-terminal 6-His tail.
Protein expression was induced during 2.5 hours with 1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG, Qbiogen, Basel,
Switzerland). The expressed proteins were purified under non
denaturating conditions as previously described [20] and concen-
trated using a MacrosepR 10K (Pall Corporation, Port Washing-
ton, USA). Final protein concentrations were determined using the
Bradford Quick StartTM assay (Biorad).
Micro-immunofluorescence assay (MIF)
Purified bacteria were inactivated by incubation with 0.3%
formalin during 1 hour at room temperature before being spotted
on MIF glass slides (12 well diagnostic slides, Menzel, Braunsch-
weig, Germany) previously washed with 70% ethanol. Slides were
pre-incubated with PBS 1% BSA during 1.5 hours at room
temperature in a humidified chamber, then washed for 5 minutes
with PBS 0.03% Tween 20, 5 minutes with PBS and 5 minutes
with distilled water. Human sera to be tested were diluted 1/32 in
PBS 1% BSA and added to the antigens as a 25 ml drop. After one
hour incubation at room temperature in a humidified chamber,
slides were washed as before. Slides were then incubated one hour
at room temperature with a 1/400 dilution of goat anti human
IgH-fluorescein conjugated (Fluoline H, Biomerieux, France) and
150 ng/ml DAPI (dilactate, Molecular Probes, OR, USA) in PBS
1% BSA. After 3 washing steps as before, slides were mounted in
Mowiol (Sigma-Aldrich, MO, USA). Positive, negative or doubtful
immunofluorescence signals were determined by two independent
investigators using an epifluorescent microscope (Axioplan 2,
Zeiss, Feldbach, Switzerland) at a magnification of 1006.
ELISA
Optimization of signal:noise ratio. To optimize the assay
with human sera, different saturation and washing conditions were
compared. Buffers used to block and to dilute primary and
secondary antibodies were:
condition 1: PBS, 0.1% Tween 20, 1% non-fat dry milk
condition 2: 20 mM Tris-HCl pH 7.5, 0.11 M NaCl, 0.1%
Tween-20, 10% FCS, 1% BSA, 1% casein, 1% PEG
condition 3: same as condition 2 but 0.5 M NaCl
condition 4: same as condition 2 but 1 M NaCl
condition 5: same as condition 2 but 1.5 M NaCl
For each condition, a related washing buffer was used:
condition 1: PBS, 0.1% Tween-20
condition 2: 20 mM Tris-HCl pH 7.5, 0.11 M NaCl, 0.1%
Tween-20
condition 3: same as condition 2 but 0.5 M NaCl
condition 4: same as condition 2 but 1 M NaCl
condition 5: same as condition 2 but 1.5 M NaCl.
In the optimization phase, human sera were diluted 1/16, 1/32,
1/64 and 1/128. Secondary antibody (horseradish peroxidase-
conjugated goat anti-human IgH (Chemicon, Temecula, CA)) was
diluted 1/5’000, 1/10’000, 1/25’000 and 1/50’000. The enzy-
matic reaction with O-phenylenediamine dihydrochloride (OPD)
as substrate was stopped with 3M H2SO4 after 5, 15 or 45 minutes
and the optical density was read at 492 nm using an ELISA reader
(Multiskan Ascent, Thermo Scientific, Waltham, USA). ROC
analyses of the ELISA outcome were performed with GraphPad
Prism version 5.04 for Windows (GraphPad Software, San Diego,
CA, USA).
Wim3 assay. 96-well microplates were coated during
12 hours at 4uC with 100 ng/well of purified protein in
carbonate/bicarbonate buffer pH 9.6. Saturation as well as
primary and secondary antibody dilutions were performed in
20 mM Tris-HCl pH 7.5, 0.11 M NaCl, 0.1% Tween-20, 10%
FCS, 1% BSA, 1% casein, 1% PEG. The saturation step of 1 hour
at 37uC was followed by one washing step with 20 mM Tris-HCl
pH 7.5, 0.11 M NaCl, 0.1% Tween-20 and a 2 hours incubation
at 37uC with primary antibodies diluted 1/64. After 5 washing
steps, the plates were incubated during 1 hour at 37uC with a 1/
5000 dilution of horseradish peroxidase-conjugated goat anti-
human IgH. After 5 washing steps, substrate (1 mg/ml O-
phenylenediamine dihydrochloride in citrate buffer) was added
and the enzymatic reaction was stopped with 3M H2SO4 after
5 minutes. The optical density was read at 492 nm.
Wim4 assay. Same protocol as for Wim3 assay except that
saturation and primary/secondary antibody dilutions were
performed in PBS, 0.1% Tween-20, 1% milk and that washing
steps were performed using PBS, 0.1% Tween-20. The enzymatic
reaction was stopped after 15 minutes.
When testing rabbit sera, ELISA were performed as described
elsewhere [20].
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